Two-dose Primary Vaccination With Either GSK Biologicals' 10-valent Pneumococcal Vaccine (Synflorix) or Pfizer's Prevenar 13 or Both Vaccines Followed by a Booster Dose of Synflorix

Trial Profile

Two-dose Primary Vaccination With Either GSK Biologicals' 10-valent Pneumococcal Vaccine (Synflorix) or Pfizer's Prevenar 13 or Both Vaccines Followed by a Booster Dose of Synflorix

Completed
Phase of Trial: Phase III

Latest Information Update: 08 Oct 2017

At a glance

  • Drugs Pneumococcal 10-valent vaccine conjugate (Primary) ; Pneumococcal 13-valent CRM197 vaccine conjugate (Primary)
  • Indications Pneumococcal infections
  • Focus Adverse reactions; Registrational
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 08 Oct 2017 Results exploring interchangeability of PCVs presented at the IDWeek 2017
    • 29 May 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 12 Sep 2013 Planned end date changed from 1 May 2014 to 1 Jun 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top